CDK2 and melanoma: These results are consistent with CDK2 being a downstream target of the MITF transcription factor in melanoma [24], as previous work has shown that all of the cell lines in the NCI-60 cell line panel with MITF amplification also harbored a BRAF V600E mutation [33].